Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•04/11/2026•07:00 ET
0
Key Highlights
- ➤$387 million cash, equivalents and securities expected to fund operations into second half of 2028
- ➤OD-001 Phase 2a analyses reinforce clinical proof of concept in ulcerative colitis
- ➤OD-002 completed IND-enabling studies as Phase 1/2a trial targets first half of 2027
- ➤Third-quarter net loss $53.1 million versus $35.5 million in 2025
- ➤OD-001 Phase 2b and combination-trial topline results expected second half of 2027
Expert Statements
Gary D. Glick, Founder and chief executive officer of Odyssey Therapeutics
“Over the past several months, we have made meaningful progress across our entire pipeline, highlighted by additional analyses from the Phase 2a induction period for OD-001 demonstrating that clinical efficacy is supported by concordant biomarker and transcriptomic findings, further reinforcing previously established clinical proof of concept in patients with ulcerative colitis.”
Gary D. Glick, Founder and chief executive officer of Odyssey Therapeutics
“We have also continued to advance the clinical development of OD-001 while completing IND-enabling studies for OD-002, our SLC15A4 inhibitor. Together with an enhanced executive leadership team and strong financial foundation, these achievements position us to execute on our clinical development strategy and drive continued progress throughout our portfolio.”
Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis
Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor
Get started
Create a free account to read the full story.